Loading organizations...
§ Private Profile · Seoul, Seoul-t'ukpyolsi, South Korea
Biotechnology company developing and manufacturing exosome pharmaceuticals and cosmeceuticals for regenerative medicine and medical aesthetics.
Founded in January 2017 by Byong Seung Cho, ExoCoBio is a biotechnology company headquartered in Seoul, South Korea, that develops and manufactures exosome-based products derived from adipose stem cells for regenerative medicine and medical aesthetics. The enterprise has secured approximately $47 million in venture capital funding from institutional investors including Seven Tree Equity Partners, CSQUARED Global Asset Management, Intervest, and TS Investment Partners. This significant financial backing directly supports the development of a specialized manufacturing facility and ongoing clinical research targeting inflammatory skin diseases. With a workforce of 61 employees, the organization generates approximately $8,500,000 in annual revenue, holds over 40 patents, and has successfully sold more than 3,500,000 product cases globally. To further expand its international distribution network across the United States and other global markets, the firm acquired the medical aesthetics brand BENEV.
ExoCoBio has raised $36.3M across 2 funding rounds.
ExoCoBio has raised $36.3M in total across 2 funding rounds.
ExoCoBio has raised $36.3M across 2 funding rounds. Most recently, it raised $9.3M Series C in August 2020.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Aug 26, 2020 | $9.3M Series C | — | — | Announced |
| Sep 12, 2018 | $27M Series B | — | Atinum Investment, Csquared Global Asset Management, Future Play, GU Equity Partners, Intervest, K2 Investment, Platinum Technology Investment, Quantum Ventures Korea, Seven Tree Equity Partners, TS Investment | Announced |
ExoCoBio has raised $36.3M in total across 2 funding rounds.
ExoCoBio's investors include Atinum Investment, CSQUARED Global Asset Management, Future Play, GU Equity Partners, InterVest, K2 Investment, Platinum Technology Investment, Quantum Ventures Korea, Seven Tree Equity Partners, TS Investment.